肝细胞癌
癌症研究
下调和上调
生物
癌症
肿瘤进展
基因
遗传学
作者
Tianze Liu,Hairun Gan,Simeng He,Jia Deng,Xinyan Hu,Luting Li,Li Cai,Jianzhong He,Haoyu Long,Jianxun Cai,Hanjie Li,Qianqian Zhang,Lijie Wang,Fangbin Chen,Yu‐Ming Chen,Haopei Zhang,Jian Li,Lukun Yang,Ye Liu,Jian-Hua Yang
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2022-06-28
卷期号:82 (17): 3074-3087
被引量:32
标识
DOI:10.1158/0008-5472.can-21-3748
摘要
Abstract Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies. Elucidating the underlying mechanisms of this disease could provide new therapeutic strategies for treating HCC. Here, we identified a novel role of DEAD-box helicase 24 (DDX24), a member of the DEAD-box protein family, in promoting HCC progression. DDX24 levels were significantly elevated in HCC tissues and were associated with poor prognosis of HCC. Overexpression of DDX24 promoted HCC migration and proliferation in vitro and in vivo, whereas suppression of DDX24 inhibited both functions. Mechanistically, DDX24 bound the mRNA618–624nt of laminin subunit beta 1 (LAMB1) and increased its stability in a manner dependent upon the interaction between nucleolin and the C-terminal region of DDX24. Moreover, regulatory factor X8 (RFX8) was identified as a DDX24 promoter-binding protein that transcriptionally upregulated DDX24 expression. Collectively, these findings demonstrate that the RFX8/DDX24/LAMB1 axis promotes HCC progression, providing potential therapeutic targets for HCC. Significance: The identification of a tumor-promoting role of DDX24 and the elucidation of the underlying regulatory mechanism provide potential prognostic indicators and therapeutic approaches to help improve the outcome of patients with hepatocellular carcinoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI